Psoriasis

ATLANTA — Guselkumab, administered either every 4 or 8 weeks, is efficacious for joint and skin symptoms, as well as physical function and quality of life, among patients with active psoriatic arthritis who are biologic-naive or previously received TNF inhibitors, according to data presented at ACR/ARP 2019.

Most physicians tend to be skeptical of fad health trends. Goat yoga and appetite suppressant lollipops are shockingly — shockingly — popular in certain social media circles, but whether they actually work toward the desired end is another matter altogether.

Children with either inflammatory bowel disease, chronic noninfectious osteomyelitis or juvenile idiopathic arthritis developed psoriasis at an increased rate compared with the general public, with the highest rates seen among those treated with TNF inhibitors, according to data published in Arthritis Care & Research.

In the most popular Healio Dermatology story last week, Suzanne Bruce, MD, presented findings at the American Society for Dermatologic Surgery annual meeting from her research weighing the positives and negatives of private equity to help her decide how to transition her dermatology practice to allow more time with her family.

Metabolic syndrome status numerically affected the median Psoriasis Area and Severity Index score changes in patients receiving Ilumya 100 mg or 200 mg or Enbrel but was not clinically lower, according to research presented at the Academy of Managed Care Pharmacy Nexus.

Ilumya is among the most cost-effective first-line therapies for treating psoriasis, according to research presented by Justin Carrico, MD, of RTI Health Solutions, and colleagues at Academy of Managed Care Pharmacy Nexus.

Since 2004, World Psoriasis Day has been celebrated on Oct. 29.

Treatment with bimekizumab, an interleukin-17A and IL-17F inhibitor in adults with chronic plaque psoriasis, resulted in at least a 90% improvement in the Psoriasis Area and Severity Index and Investigator Global Assessment score of clear or almost clear, according to phase 3 results from the development program BE VIVID by UCB.

Phase 3 data presented at the European Academy of Dermatology and Venereology Congress demonstrated that treatment with Taltz resulted in a 75% improvement in Psoriasis Area of Severity Index score and static Physician Global Assessment of clear or almost clear skin at 12 weeks in pediatric patients with moderate to severe plaque psoriasis.

An increase in overall cancer mortality risk was found in patients with severe psoriasis, and associations were identified within site-specific cancers such as colon and kidney among patients with all severities of psoriasis, according to a systematic review of 58 studies that was published in JAMA Dermatology.